Table 1.

Recommended treatment of HCV infection in patients with chronic kidney disease.

Stage of CKD	IFN	Ribavirin
1 and 2	Pegylated IFN α-2a: 180 μg weekly by subcutaneous route Pegylated IFN α-2b: 1.5 μg/kg−1 weekly by subcutaneous route	800–1200 mg day−1 in two divided doses (by oral route)
3 and 4	Pegylated IFN α-2a: 135 μg weekly by subcutaneous route Pegylated IFN α-2b: 1.0 μg/kg−1 weekly by subcutaneous route	Stage 3: 400–800 mg day−1 in two divided doses (by oral route) 200–400 mg daily (by oral route) for eGFR <50 mL/min per 1.73 m2
5	Pegylated IFN α-2a: 135 μg weekly by subcutaneous route Pegylated IFN α-2b: 1.0 μg/kg−1 weekly by subcutaneous route	200–400 daily (by oral route)
5D	Standard IFN α-2a: 3 mU thrice weekly by subcutaneous route Standard IFN α-2b: 1 μg kg−1 weekly by subcutaneous route or Pegylated IFN α-2a: 135 μg weekly by subcutaneous route Pegylated IFN α-2b: 1 μg kg−1 weekly by subcutaneous route	200 mg daily or 200 mg thrice weekly (by oral route)